Please use this identifier to cite or link to this item: https://hdl.handle.net/11147/8906
Title: Curcumin: Novel treatment in neonatal hypoxic-ischemic brain injury
Authors: Rocha-Ferreira, Eridan
Sisa, Claudia
Bright, Sarah
Fautz, Tessa
Harris, Michael
Riquelme, Ingrid Contreras
Kurulday, Tuğçe
Hristova, Mariya
Keywords: Curcumin
Hypoxia
Ischemia
Neuroprotection
Neonate
Oxidative stress
Issue Date: 2019
Publisher: Frontiers Media S.A.
Abstract: Hypoxic-ischemic encephalopathy (HIE) is a major cause of mortality and morbidity in neonates, with an estimated global incidence of 3/1,000 live births. HIE brain damage is associated with an inflammatory response and oxidative stress, resulting in the activation of cell death pathways. At present, therapeutic hypothermia is the only clinically approved treatment available for HIE. This approach, however, is only partially effective. Therefore, there is an unmet clinical need for the development of novel therapeutic interventions for the treatment of HIE. Curcumin is an antioxidant reactive oxygen species scavenger, with reported anti-tumor and anti-inflammatory activity. Curcumin has been shown to attenuate mitochondrial dysfunction, stabilize the cell membrane, stimulate proliferation, and reduce injury severity in adult models of spinal cord injury, cancer, and cardiovascular disease. The role of curcumin in neonatal HIE has not been widely studied due to its low bioavailability and limited aqueous solubility. The aim of this study was to investigate the effect of curcumin treatment in neonatal HIE, including time of administration and dose-dependent effects. Our results indicate that curcumin administration prior to HIE in neonatal mice elevated cell and tissue loss, as well as glial activation compared to HI alone. However, immediate post-treatment with curcumin was significantly neuroprotective, reducing grey and white matter tissue loss, TUNEL+ cell death, microglia activation, reactive astrogliosis, and iNOS oxidative stress when compared to vehicle-treated littermates. This effect was dose-dependent, with 200 mu g/g body weight as the optimal dose-regimen, and was maintained when curcumin treatment was delayed by 60 or 120 min post-HI. Cell proliferation measurements showed no changes between curcumin and HI alone, suggesting that the protective effects of curcumin on the neonatal brain following HI are most likely due to curcumin's anti-inflammatory and antioxidant properties, as seen in the reduced glial and iNOS activity. In conclusion, this study suggests curcumin as a potent neuroprotective agent with potential for the treatment of HIE. The delayed application of curcumin further increases its clinical relevance.
Description: PubMed: 31798458
URI: https://doi.org/10.3389/fphys.2019.01351
https://hdl.handle.net/11147/8906
ISSN: 1664-042X
Appears in Collections:Molecular Biology and Genetics / Moleküler Biyoloji ve Genetik
PubMed İndeksli Yayınlar Koleksiyonu / PubMed Indexed Publications Collection
Scopus İndeksli Yayınlar Koleksiyonu / Scopus Indexed Publications Collection
WoS İndeksli Yayınlar Koleksiyonu / WoS Indexed Publications Collection

Files in This Item:
File SizeFormat 
fphys-10-01351.pdf16.24 MBAdobe PDFView/Open
Show full item record



CORE Recommender

SCOPUSTM   
Citations

27
checked on Mar 1, 2024

WEB OF SCIENCETM
Citations

24
checked on Mar 2, 2024

Page view(s)

166
checked on Mar 4, 2024

Download(s)

112
checked on Mar 4, 2024

Google ScholarTM

Check




Altmetric


Items in GCRIS Repository are protected by copyright, with all rights reserved, unless otherwise indicated.